Two types of amphoteric calix[n]arene carboxylic acid (CnCA) derivative, i.e., calix[6]arene hexa-carboxylic acid (C6HCA) and calix[8]arene octo-carboxylic acid (C8OCA), were synthesized by introducing acetoxyls into the hydroxyls of calix[n]arene (n=6, 8). C6HCA and C8OCA nanoparticles (NPs) were prepared successfully using the dialysis method. CnCA NPs had regular spherical shapes with an average diameter of 180–220 nm and possessed negative charges of greater than −30 mV. C6HCA and C8OCA NPs were stable in 4.5% bovine serum albumin solutions and buffers (pH 5–9), with a low critical aggregation concentration value of 5.7 mg·L−1 and 4.0 mg·L−1, respectively. C6HCA and C8OCA NPs exhibited good paclitaxel (PTX) loading capacity, with drug loading contents of 7.5% and 8.3%, respectively. The overall in vitro release behavior of PTX from the CnCA NPs was sustained, and C8OCA NPs had a slower release rate compared with C6HCA NPs. These favorable properties of CnCA NPs make them promising nanocarriers for tumor-targeted drug delivery.
通过在
钙[n]炔(n=6,8)的羟基中引入乙酰氧基,合成了两种两性
钙[n]炔
羧酸(CnCA)衍
生物,即
钙[6]炔六
羧酸(C6HCA)和
钙[8]炔八
羧酸(C8OCA)。采用透析法成功制备了 C6HCA 和 C8OCA 纳米粒子(NPs)。CnCA NPs呈规则球形,平均直径为180-220 nm,带有大于-30 mV的负电荷。C6HCA 和 C8OCA NPs 在 4.5%
牛血清白蛋白溶液和缓冲液(pH 5-9)中稳定,临界聚集浓度值分别为 5.7 mg-L-1 和 4.0 mg-L-1。C6HCA 和 C8OCA NPs 具有良好的
紫杉醇(
PTX)负载能力,药物负载率分别为 7.5% 和 8.3%。
PTX 从 CnCA NPs 中的体外释放行为总体上是持续的,与 C6HCA NPs 相比,C8OCA NPs 的释放速率较慢。CnCA NPs 的这些有利特性使其成为肿瘤靶向给药的理想纳米载体。